AIDS vaccine : Intranasal immunization using inactivated HIV-1-capturing core-corona type polymeric nanospheres
Identifieur interne : 001030 ( Main/Exploration ); précédent : 001029; suivant : 001031AIDS vaccine : Intranasal immunization using inactivated HIV-1-capturing core-corona type polymeric nanospheres
Auteurs : Takami Akagi [Japon] ; Masamichi Ueno [Japon] ; Katsuya Hiraishi [Japon] ; Masanori Baba [Japon] ; Mitsuru Akashi [Japon]Source :
- Journal of controlled release [ 0168-3659 ] ; 2005.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Vaccin.
English descriptors
- KwdEn :
Abstract
Polymeric nanospheres have been widely used in biomedical applications, such as drug, gene and vaccine delivery systems. Nanospheres with entrapped antigens have recently been shown to possess significant potential as vaccine delivery systems and adjuvants. We previously reported that concanavalin A-immobilized polystyrene nanospheres (Con A-NS) could efficiently capture HIV-1 particles and intranasal immunization with inactivated HIV-1-capturing nanospheres (HIV-NS) induced vaginal anti-HIV-1 IgA antibody responses in mice. In addition, vaginal washes from intranasally immunized mice were capable of neutralizing HIV-1. Moreover, simian/human immunodeficiency virus KU-2-capturing nanospheres (SHIV-NS) immunized macaques exhibited partial protection when vaginally and systemically challenged with pathogenic viruses. HIV-NS is suggested to be particularly suitable to enhance antigen delivery to dendritic cells (DCs). In this study, we investigated the mucosal antibody response in mice after the intravaginal or intranasal immunization in detail with using different sized (360, 660, 940 and 1230 nm) HIV-NS. The amount of immobilized Con A to NS was dependent on the surface area of the particle. Moreover, Con A-NS with different sizes could equally capture inactivated HIV-1. Intravaginal or intranasal immunization by HIV-NS with diameters ranging 360 to 1230 nm significantly induced vaginal antibody responses. However, significant differences on vaginal anti-HIV-1 gp120 IgA and IgG antibodies were not found after intravaginal or intranasal immunization with different sized HIV-NS. These results suggest that HIV-NS provides an efficient vaccine delivery system for the induction of a mucosal immune response and the development of a mucosal vaccine.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000043
- to stream PascalFrancis, to step Curation: 000016
- to stream PascalFrancis, to step Checkpoint: 000050
- to stream Main, to step Merge: 001041
- to stream Main, to step Curation: 001030
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">AIDS vaccine : Intranasal immunization using inactivated HIV-1-capturing core-corona type polymeric nanospheres</title><author><name sortKey="Akagi, Takami" sort="Akagi, Takami" uniqKey="Akagi T" first="Takami" last="Akagi">Takami Akagi</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Applied Chemistry, Graduate School of Engineering, Osaka University</s1><s2>2-1 Yamadaoka, Suita 565-0871</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>2-1 Yamadaoka, Suita 565-0871</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST)</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Ueno, Masamichi" sort="Ueno, Masamichi" uniqKey="Ueno M" first="Masamichi" last="Ueno">Masamichi Ueno</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Japan Immunoresearch Laboratories</s1><s2>Takasaki</s2><s3>JPN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Japan Immunoresearch Laboratories</wicri:noRegion></affiliation></author><author><name sortKey="Hiraishi, Katsuya" sort="Hiraishi, Katsuya" uniqKey="Hiraishi K" first="Katsuya" last="Hiraishi">Katsuya Hiraishi</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Japan Immunoresearch Laboratories</s1><s2>Takasaki</s2><s3>JPN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Japan Immunoresearch Laboratories</wicri:noRegion></affiliation></author><author><name sortKey="Baba, Masanori" sort="Baba, Masanori" uniqKey="Baba M" first="Masanori" last="Baba">Masanori Baba</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST)</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University</s1><s2>Kagoshima</s2><s3>JPN</s3><sZ>4 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kagoshima</wicri:noRegion></affiliation></author><author><name sortKey="Akashi, Mitsuru" sort="Akashi, Mitsuru" uniqKey="Akashi M" first="Mitsuru" last="Akashi">Mitsuru Akashi</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Applied Chemistry, Graduate School of Engineering, Osaka University</s1><s2>2-1 Yamadaoka, Suita 565-0871</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>2-1 Yamadaoka, Suita 565-0871</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST)</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">06-0210285</idno><date when="2005">2005</date><idno type="stanalyst">PASCAL 06-0210285 INIST</idno><idno type="RBID">Pascal:06-0210285</idno><idno type="wicri:Area/PascalFrancis/Corpus">000043</idno><idno type="wicri:Area/PascalFrancis/Curation">000016</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000050</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000050</idno><idno type="wicri:doubleKey">0168-3659:2005:Akagi T:aids:vaccine:intranasal</idno><idno type="wicri:Area/Main/Merge">001041</idno><idno type="wicri:Area/Main/Curation">001030</idno><idno type="wicri:Area/Main/Exploration">001030</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">AIDS vaccine : Intranasal immunization using inactivated HIV-1-capturing core-corona type polymeric nanospheres</title><author><name sortKey="Akagi, Takami" sort="Akagi, Takami" uniqKey="Akagi T" first="Takami" last="Akagi">Takami Akagi</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Applied Chemistry, Graduate School of Engineering, Osaka University</s1><s2>2-1 Yamadaoka, Suita 565-0871</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>2-1 Yamadaoka, Suita 565-0871</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST)</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Ueno, Masamichi" sort="Ueno, Masamichi" uniqKey="Ueno M" first="Masamichi" last="Ueno">Masamichi Ueno</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Japan Immunoresearch Laboratories</s1><s2>Takasaki</s2><s3>JPN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Japan Immunoresearch Laboratories</wicri:noRegion></affiliation></author><author><name sortKey="Hiraishi, Katsuya" sort="Hiraishi, Katsuya" uniqKey="Hiraishi K" first="Katsuya" last="Hiraishi">Katsuya Hiraishi</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Japan Immunoresearch Laboratories</s1><s2>Takasaki</s2><s3>JPN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Japan Immunoresearch Laboratories</wicri:noRegion></affiliation></author><author><name sortKey="Baba, Masanori" sort="Baba, Masanori" uniqKey="Baba M" first="Masanori" last="Baba">Masanori Baba</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST)</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University</s1><s2>Kagoshima</s2><s3>JPN</s3><sZ>4 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Kagoshima</wicri:noRegion></affiliation></author><author><name sortKey="Akashi, Mitsuru" sort="Akashi, Mitsuru" uniqKey="Akashi M" first="Mitsuru" last="Akashi">Mitsuru Akashi</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Applied Chemistry, Graduate School of Engineering, Osaka University</s1><s2>2-1 Yamadaoka, Suita 565-0871</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>2-1 Yamadaoka, Suita 565-0871</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST)</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Journal of controlled release</title><title level="j" type="abbreviated">J. control. release</title><idno type="ISSN">0168-3659</idno><imprint><date when="2005">2005</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Journal of controlled release</title><title level="j" type="abbreviated">J. control. release</title><idno type="ISSN">0168-3659</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AIDS</term><term>HIV-1 virus</term><term>IgA</term><term>Immunization</term><term>Intranasal administration</term><term>Nanosphere</term><term>Pharmaceutical technology</term><term>Vaccine</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>SIDA</term><term>Vaccin</term><term>Voie intranasale</term><term>Immunisation</term><term>Virus HIV1</term><term>Nanosphère</term><term>IgA</term><term>Technologie pharmaceutique</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Polymeric nanospheres have been widely used in biomedical applications, such as drug, gene and vaccine delivery systems. Nanospheres with entrapped antigens have recently been shown to possess significant potential as vaccine delivery systems and adjuvants. We previously reported that concanavalin A-immobilized polystyrene nanospheres (Con A-NS) could efficiently capture HIV-1 particles and intranasal immunization with inactivated HIV-1-capturing nanospheres (HIV-NS) induced vaginal anti-HIV-1 IgA antibody responses in mice. In addition, vaginal washes from intranasally immunized mice were capable of neutralizing HIV-1. Moreover, simian/human immunodeficiency virus KU-2-capturing nanospheres (SHIV-NS) immunized macaques exhibited partial protection when vaginally and systemically challenged with pathogenic viruses. HIV-NS is suggested to be particularly suitable to enhance antigen delivery to dendritic cells (DCs). In this study, we investigated the mucosal antibody response in mice after the intravaginal or intranasal immunization in detail with using different sized (360, 660, 940 and 1230 nm) HIV-NS. The amount of immobilized Con A to NS was dependent on the surface area of the particle. Moreover, Con A-NS with different sizes could equally capture inactivated HIV-1. Intravaginal or intranasal immunization by HIV-NS with diameters ranging 360 to 1230 nm significantly induced vaginal antibody responses. However, significant differences on vaginal anti-HIV-1 gp120 IgA and IgG antibodies were not found after intravaginal or intranasal immunization with different sized HIV-NS. These results suggest that HIV-NS provides an efficient vaccine delivery system for the induction of a mucosal immune response and the development of a mucosal vaccine.</div></front></TEI><affiliations><list><country><li>Japon</li></country><region><li>Région de Kantō</li></region><settlement><li>Tokyo</li></settlement></list><tree><country name="Japon"><noRegion><name sortKey="Akagi, Takami" sort="Akagi, Takami" uniqKey="Akagi T" first="Takami" last="Akagi">Takami Akagi</name></noRegion><name sortKey="Akagi, Takami" sort="Akagi, Takami" uniqKey="Akagi T" first="Takami" last="Akagi">Takami Akagi</name><name sortKey="Akashi, Mitsuru" sort="Akashi, Mitsuru" uniqKey="Akashi M" first="Mitsuru" last="Akashi">Mitsuru Akashi</name><name sortKey="Akashi, Mitsuru" sort="Akashi, Mitsuru" uniqKey="Akashi M" first="Mitsuru" last="Akashi">Mitsuru Akashi</name><name sortKey="Baba, Masanori" sort="Baba, Masanori" uniqKey="Baba M" first="Masanori" last="Baba">Masanori Baba</name><name sortKey="Baba, Masanori" sort="Baba, Masanori" uniqKey="Baba M" first="Masanori" last="Baba">Masanori Baba</name><name sortKey="Hiraishi, Katsuya" sort="Hiraishi, Katsuya" uniqKey="Hiraishi K" first="Katsuya" last="Hiraishi">Katsuya Hiraishi</name><name sortKey="Ueno, Masamichi" sort="Ueno, Masamichi" uniqKey="Ueno M" first="Masamichi" last="Ueno">Masamichi Ueno</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001030 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001030 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:06-0210285
|texte= AIDS vaccine : Intranasal immunization using inactivated HIV-1-capturing core-corona type polymeric nanospheres
}}
| This area was generated with Dilib version V0.6.33. |  |